Hologic, Inc. (NASDAQ: HOLX): A New Chapter as a Women’s Health PowerhouseToday marks a definitive turning point for Hologic, Inc. (
NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
Blackstone and TPG Complete Acquisition of Hologic
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately.
A Look Back at Medical Devices & Supplies - Imaging, Diagnostics Stocks’ Q4 Earnings: Hologic (NASDAQ:HOLX) Vs The Rest Of The PackLooking back on medical devices & supplies - imaging, diagnostics stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Hologic...
The Great Credit Bifurcation: Leveraged Loan Market Plummets 34% in Q1 2026As the first quarter of 2026 comes to a close, the high-flying leveraged finance market has hit a significant turbulence zone. Data for the quarter reveals a sharp 34% decline in leveraged loan activity compared to the same period last year, marking the slowest start to a year for credit
Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction
Hologic, Inc. (Nasdaq: HOLX) announced today that Steve MacMillan, its long-time Chairman, President and Chief Executive Officer (CEO), has decided to retire when the Company’s go-private transaction with Blackstone and TPG closes.
3 Reasons to Sell HOLX and 1 Stock to Buy InsteadWhile the broader market has struggled with the S&P 500 down 1% since September 2025, Hologic has surged ahead as its stock price has climbed by 12.7% to $75...
Is Hologic Stock Outperforming the Dow?Although Hologic has exceeded the Dow over the past year, analysts remain cautious about the stock’s prospects.
1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates
Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year.
The $2.5 Trillion Tsunami: Why 2026 has Become the Year of the MegadealAs of March 10, 2026, the United States financial markets are witnessing an unprecedented explosion in Mergers and Acquisitions (M&A) that has caught even the most optimistic analysts by surprise. Driven by a historic surge in private equity confidence—now sitting at a six-year high of 86%—the deal-making
1 Unpopular Stock That Should Get More Attention and 2 Facing ChallengesWall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
The Return of the Titans: M&A Volume Set to Surge 20% in 2026 Amidst "Animal Spirits"As of March 4, 2026, the global financial landscape is witnessing a seismic shift in corporate strategy. After years of cautious maneuvering and high interest rates, the "animal spirits" of the boardroom have returned with a vengeance. Leading investment banks, including Morgan Stanley (
NYSE: MS), are now projecting a staggering
3 Cash-Producing Stocks We Find RiskyGenerating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Is Wall Street Bullish or Bearish on Hologic Stock?Though Hologic has outperformed the broader market over the past year, Wall Street analysts maintain a cautious outlook on the stock’s prospects.
Earnings To Watch: QuidelOrtho (QDEL) Reports Q4 Results TomorrowHealthcare diagnostics company QuidelOrtho (
NASDAQ:QDEL)
will be reporting earnings this Wednesday after the bell. Here’s what to expect.
The Return of the Giants: Private Equity Mega-Deals Surge in Early 2026The "Great Hesitation" in global finance has officially come to an end. In the opening weeks of 2026, the private equity landscape has undergone a dramatic transformation, shifting from two years of defensive posturing to a full-scale dealmaking renaissance. Driven by a record-shattering $2 trillion in "dry powder" and a
Hologic Receives FDA Approval for Aptima® HPV Assay Primary Screening Option, Expanding Cervical Health Portfolio
Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® HPV Assay received FDA approval for clinician-collected HPV primary screening. Hologic’s human papillomavirus (HPV) test is the only FDA-approved mRNA-based assay, designed specifically to detect infections most likely to lead to cervical cancer.
GE HealthCare (GEHC) Q4 Earnings Report Preview: What To Look ForHealthcare technology company GE HealthCare Technologies (
NASDAQ:GEHC)
will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
Hologic (NASDAQ:HOLX) Misses Q4 CY2025 Revenue EstimatesMedical technology company Hologic (
NASDAQ:HOLX) missed Wall Street’s revenue expectations in Q4 CY2025 as sales rose 2.5% year on year to $1.05 billion. Its non-GAAP profit of $1.04 per share was 5.4% below analysts’ consensus estimates.
Hologic Announces Financial Results for First Quarter of Fiscal 2026
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04.
US Credit Market: M&A and LBOs Fuel Issuance Surge in 2026The US credit market has entered 2026 with a level of momentum unseen in nearly a decade, as a powerful combination of multi-billion dollar mergers and a resurgence in leveraged buyouts (LBOs) drives primary issuance to record heights. Following the Federal Reserve’s pivot toward a more accommodative stance in
Hologic (HOLX) Q4 Earnings: What To ExpectMedical technology company Hologic (
NASDAQ:HOLX) will be reporting earnings this Thursday after market hours. Here’s what you need to know.
The Breaking of the Deal Dam: Inside the Private Equity Renaissance of 2026As of January 23, 2026, the global financial landscape is witnessing what many analysts are calling a structural "renaissance" in private equity. Led by industry titans Blackstone (
NYSE: BX) and KKR & Co. Inc. (
NYSE: KKR), the sector has shifted from a two-year period of high-interest-rate hibernation to a state of
